Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -40176.79% is 512% below its 5-year average of -6561.55%, near the low end of its 5-year range (-46754.83%–-3938.87%).
444.08% below its 12-month average of -7384.42%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2023 (2023-03-31): -9442.81%.
EBITDA MARGIN
-40176.79%
EBITDA MARGIN AVG TTM
-7384.42%
EBITDA MARGIN AVG 3Y
-13000.64%
EBITDA MARGIN AVG 5Y
-6561.55%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-444.08%
CURRENT VS 3Y AVG
-209.04%
CURRENT VS 5Y AVG
-512.31%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Gain Therapeutics, Inc.
Market Cap
$72.01M
EBITDA Margin
-40176.79%
TTM Avg
-7384.42%
3Y Avg
-13000.64%
5Y Avg
-6561.55%
Market Cap
$72.49M
EBITDA Margin
-31.36%
TTM Avg
-442.92%
3Y Avg
-595.18%
5Y Avg
-526.87%
Market Cap
$71.42M
EBITDA Margin
-85.70%
TTM Avg
-57.28%
3Y Avg
-59.72%
5Y Avg
-51.35%
Market Cap
$69.19M
EBITDA Margin
-0.04%
TTM Avg
-76.47%
3Y Avg
-54.24%
5Y Avg
-650.20%
Market Cap
$68.72M
EBITDA Margin
-8394.83%
TTM Avg
-8394.83%
3Y Avg
-4949.66%
5Y Avg
-3042.42%
Market Cap
$68.60M
EBITDA Margin
-103.63%
TTM Avg
-143.63%
3Y Avg
-176.25%
5Y Avg
-194.05%
Market Cap
$75.56M
EBITDA Margin
1.51%
TTM Avg
-4.98%
3Y Avg
-8.74%
5Y Avg
-7.62%
Market Cap
$75.78M
EBITDA Margin
-257.20%
TTM Avg
-292.35%
3Y Avg
-520.13%
5Y Avg
-2376.66%
Market Cap
$75.82M
EBITDA Margin
-58.13%
TTM Avg
-62.55%
3Y Avg
-79.72%
5Y Avg
-85.39%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $72.01M | -40176.79% | -7384.42% | -13000.64% | -6561.55% |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.49M | -31.36% | -442.92% | -595.18% | -526.87% |
| MindWalk Holdings Corp. (HYFT)vs › | $71.42M | -85.70% | -57.28% | -59.72% | -51.35% |
| Spero Therapeutics, Inc. (SPRO)vs › | $69.19M | -0.04% | -76.47% | -54.24% | -650.20% |
| Tiziana Life Sciences Ltd (TLSA)vs › | $68.72M | -8394.83% | -8394.83% | -4949.66% | -3042.42% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.60M | -103.63% | -143.63% | -176.25% | -194.05% |
| SkinHealth Systems Inc. (SKIN)vs › | $75.56M | 1.51% | -4.98% | -8.74% | -7.62% |
| Hyperfine, Inc. (HYPR)vs › | $75.78M | -257.20% | -292.35% | -520.13% | -2376.66% |
| Pulmonx Corporation (LUNG)vs › | $75.82M | -58.13% | -62.55% | -79.72% | -85.39% |
| Champions Oncology, Inc. (CSBR)vs › | $67.66M | 0.40% | 5.90% | -0.59% | 0.99% |
Gross Margin
0.0%
EBITDA Margin
-40176.8%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2023-03-31 | -9442.81% |
| 2022-06-30 | -5421.93% |
| 2022-03-31 | -7288.51% |
| 2021-12-31 | -7412.94% |
| 2021-09-30 | -16938.34% |
| 2021-06-30 | -3938.87% |
| 2021-03-31 | -46754.83% |
| 2020-12-31 | -17647.46% |
| 2020-09-30 | -12196.95% |
| 2020-06-30 | -8319.30% |
| 2020-03-31 | -7645.12% |
| 2019-09-30 | -5078.78% |
| 2019-06-30 | -5078.78% |
| 2019-03-31 | -5078.78% |
| 2018-09-30 | -4986.30% |
| 2018-06-30 | -4986.30% |
| 2018-03-31 | -4986.30% |
